1. Serotonergic Approaches in Parkinson’s Disease: Translational Perspectives, an Update
- Author
-
Andrew C. McCreary, Véronique Sgambato-Faure, Philippe Huot, and Susan H. Fox
- Subjects
0301 basic medicine ,Serotonin ,Psychosis ,Parkinson's disease ,Physiology ,Cognitive Neuroscience ,Disease ,Motor Activity ,Serotonergic ,Biochemistry ,Antiparkinson Agents ,Translational Research, Biomedical ,03 medical and health sciences ,chemistry.chemical_compound ,Serotonin Agents ,0302 clinical medicine ,Dopamine ,medicine ,Animals ,Humans ,Neurotransmitter ,Dopaminergic ,Parkinson Disease ,Cell Biology ,General Medicine ,medicine.disease ,3. Good health ,Disease Models, Animal ,030104 developmental biology ,chemistry ,Dyskinesia ,medicine.symptom ,Psychology ,Neuroscience ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Parkinson's disease (PD) has long been seen as a disorder caused by degeneration of the dopaminergic system, leading to the classic motor manifestations of the disease. However, there is now overwhelming evidence that PD is more than a disease merely caused by dopamine depletion. It is well-known that a myriad of other neurotransmitters are affected by the disease process. One such neurotransmitter is serotonin (5-HT). 5-HT has been shown to play a role in several motor and nonmotor manifestations of PD, including tremor, cognition, depression and psychosis. 5-HT also seems to play a critical role in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. A breadth of preclinical studies and clinical trials have been conducted that aimed at modulating the 5-HT system in order to alleviate depression, cognitive deficits, psychosis, and dyskinesia. In this Review, we summarize recent advances in the 5-HT field in PD, but with a translational emphasis. We start by presenting a novel nonhuman primate model of PD that presents with dual dopamine and 5-HT lesions. We then present preclinical and clinical data that introduce new concepts, such as the use of biased and partial agonists, as well as molecules recently introduced to the field of PD, such as eltoprazine, pimavanserin, nelotanserin, and SYN-120, to enhance therapeutic benefit while minimizing adverse events, notably on parkinsonian disability.
- Published
- 2017